研究睾酮治疗对跨性别男性生殖影响的小鼠模型
该研究使用20只C57BL/6N雌鼠,皮下注射庚酸睾酮0.225、0.45或0.90 mg每周两次共6周,0.90 mg组5只中2只出现阴道脱垂被排除;0.225和0.45 mg组出现持续间情期、LH抑制、无黄体,0.45 mg组晚期窦卵泡闭锁囊样增加,但卵泡计数未减少。
要点
- 庚酸睾酮0.45 mg每周两次皮下注射可用于青春期后C57BL/6N雌鼠模型。
- 0.225和0.45 mg组出现持续间情期、LH抑制和无黄体。
- 0.45 mg组晚期窦卵泡闭锁囊样增加,但卵泡计数未减少。
核心结论
- 庚酸睾酮0.45 mg每周两次皮下注射可用于青春期后C57BL/6N雌鼠以研究跨性别男性睾酮治疗的生殖影响。
- 该模型支持睾酮治疗通过LH抑制、持续间情期和无黄体抑制下丘脑-垂体-性腺轴。
- 晚期窦卵泡闭锁囊样增加与跨性别男性睾酮治疗病例系列中多囊卵巢形态患病率增加一致,结果也提示睾酮治疗不耗竭卵巢储备。
研究设计与样本
- 研究使用20只C57BL/6N雌鼠,每组5只,包括芝麻油溶剂对照和三个庚酸睾酮剂量组(0.225、0.45和0.90 mg)。
- 小鼠在8-9周龄开始皮下注射,每周两次,持续6周。
- 治疗前进行每日阴道细胞学检查确认所有小鼠有周期。
主要发现
- 0.90 mg庚酸睾酮组5只中2只出现阴道脱垂,该组被排除进一步分析。
- 0.225或0.45 mg庚酸睾酮每周两次导致周期停止和持续间情期;0.225 mg组5只中1只在治疗2.5周后恢复周期。
- 与对照相比,睾酮治疗小鼠终末血样中睾酮水平持续升高且促黄体生成素(LH)受抑制。
- 与对照相比,睾酮治疗小鼠阴蒂面积增加,0.45 mg组晚期窦卵泡闭锁囊样增加。
- 与对照相比,睾酮治疗小鼠原始、初级、次级或总窦卵泡计数未检测到减少,且无黄体。
局限性
- 小鼠模型可提供相关关键发现供进一步探索,但可能不完全模拟人类生殖生理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can mice serve as a translational model to investigate the reproductive effects of testosterone (T) therapy commonly used by transgender men? SUMMARY ANSWER: T enanthate subcutaneous injections at 0.45 mg twice weekly can be used in the postpubertal C57BL/6N female mouse to investigate the reproductive effects of T therapy given to transgender men. WHAT IS KNOWN ALREADY: Most models of T treatment in female mice involve prenatal or prepubertal administration, which are not applicable to transgender men who often begin T therapy after puberty. Studies that have looked at the impact of postpubertal T treatment in female mice have generally not investigated reproductive outcomes. STUDY DESIGN, SIZE, DURATION: A total of 20 C57BL/6N female mice were used for this study. Study groups (n = 5 mice per group) included sesame oil vehicle controls and three doses of T enanthate (0.225, 0.45 and 0.90 mg). Mice were injected subcutaneously twice weekly for 6 weeks. PARTICIPANTS/MATERIALS, SETTING, METHODS: Daily vaginal cytology was performed prior to initiation of treatment to confirm that all mice were cycling. At 8-9 weeks of age, therapy with subcutaneous T enanthate (0.225, 0.45 or 0.90 mg) or the vehicle control was begun. T therapy continued for 6 weeks, at which point mice were sacrificed and compared to control mice sacrificed during diestrus/metestrus. Data collected included daily vaginal cytology, weekly and terminal reproductive hormone levels, terminal body/organ weights/measurements, ovarian follicular distribution/morphology and corpora lutea counts. MAIN RESULTS AND THE ROLE OF CHANCE: Of the mice treated with 0.90 mg T enanthate, two of five mice experienced vaginal prolapse, so this group was excluded from further analysis. T enanthate administration twice weekly at 0.225 or 0.45 mg resulted in cessation of cyclicity and persistent diestrus. One of five mice at the 0.225-mg dose resumed cycling after 2.5 weeks of T therapy. As compared to controls, T-treated mice had sustained elevated T levels and luteinizing hormone (LH) suppression in the terminal blood sample. T-treated mice demonstrated increases in clitoral area and atretic cyst-like late antral follicles (0.45 mg only) as compared to controls. No reduction in primordial, primary, secondary or total antral follicle counts was detected in T-treated mice as compared to controls, and T-treated mice demonstrated an absence of corpora lutea. LIMITATIONS, REASONS FOR CAUTION: Mouse models can provide us with relevant key findings for further exploration but may not perfectly mirror human reproductive physiology. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this report describes the first mouse model mimicking T therapy given to transgender men that facilitates analysis of reproductive changes. This model allows for future studies comparing duration and reversibility of T-induced changes, on the reproductive and other systems. It supports a role for T therapy in suppressing the hypothalamic-pituitary-gonadal axis in adult female mice as evidenced by LH suppression, persistent diestrus and absence of corpora lutea. The increase in atretic cyst-like late antral follicles aligns with the increased prevalence of polycystic ovary morphology seen in case series of transgender men treated with T therapy. The results also suggest that T therapy does not deplete the ovarian reserve. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the American Society for Reproductive Medicine/Society of Reproductive Endocrinology and Infertility Grant and NIH R01-HD098233 to M.B.M. and University of Michigan Office of Research funding (U058227). H.M.K. was supported by the Career Training in Reproductive Biology and Medical Scientist Training Program T32 NIH Training Grants (T32-HD079342, T32-GM07863) as well as the Cellular and Molecular Biology Program. The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core is supported by the Eunice Kennedy Shriver NICHD/NIH (NCTRI) Grant P50-HD28934. E.E.M. consults for Allergan. No other authors have competing interests.
引用
- Kinnear HM, Constance ES, David A, et al. A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men. Hum Reprod. 2019. PMID: 31585007. doi:10.1093/humrep/dez177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。